

Supplementary Material

Loss of NQO1 generates genotoxic estrogen-DNA adducts in Fuchs Endothelial Corneal Dystrophy

Taiga Miyajima^{a,b}, Geetha Melangath^a, Shan Zhu^a, Neha Deshpande^a, Shivakumar Vasanth^a, Bodhisattwa Mondal^c, Varun Kumar^a, Yuming Chen^a, Marianne Price^d, Francis Price Jr.^d, Eleanor G. Rogan^c, Muhammad Zahid^c, Ula Jurkunas^{a*}

^a Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA

^b Department of Ophthalmology, Dokkyo Medical University, Tochigi, 321-0293, Japan

^c Department of Environmental, Agricultural and Occupational Health, College of Public Health, University of Nebraska Medical Center, Omaha, NE

^d Price Vision Group, Indianapolis, IN, USA

* Corresponding author: Ula V. Jurkunas, M.D., Associate Professor, Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, 20 Staniford Street, Room 245, Boston, MA, USA 02114

Supplemental Figure 1




Fig. 1. A. Bar graph plotting the relative amplification of small mtDNA in 30 μM 4-OHE₂ treated HCEnc-SV-67F-16, FECD-SV-73F-74 and -61F-18 cells. Dotted line indicate the untreated samples to which the treated samples are normalized. **B, C.** Survival plots of the percent cell viability of HCEnc-21T cells treated with varying doses of MN and 4-OHE₂ determined by Cell Titer Glo assay.

Supplemental Figure 2




Fig. 2. A-C. Comparison of the levels of estrogen-DNA adducts, 4-OCH₃E₂ and quinone conjugates in untreated HCEnc-21T cells *versus* treated with either 8.5 μ M MN alone, 3.75 μ M 4-OHE₂ alone or co-treated with 8.5 μ M MN and 3.75 μ M 4-OHE₂ by UPLC-MS/MS.